Human Immunodeficiency Virus (HIV) Drugs Market Size Worth $47.48 Billion By 2030 | CAGR: 5.2%

The global Human Immunodeficiency Virus (HIV) drugs market size is expected to reach USD 47.48 billion by 2030 according to a new study by Polaris Market Research. The report “Human Immunodeficiency Virus (HIV) Drugs Market Share, Size, Trends, Industry Analysis Report, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others); By Drug Class; By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Factors such as rising FDA approvals by the governments for HIV treatment across the globe are driving the industry growth during the forecast period. For instance, in December 2021, Apretude was licensed by the US Food and Drug Administration for pre-exposure prophylaxis (PrEP) in at-risk adults and youth weighing at least 35 kg to minimize the risk of sexually transmitted HIV. In January 2021, Cabenuva was approved by the US Food and Drug Administration for the diagnosis of human immunodeficiency virus type 1 (HIV-1) infectious disease in adults who are virologically suppressed on a secure antiretroviral treatment plan, have no history of therapeutic failure, and have no suspected or confirmed resistance towards either cabotegravir or rilpivirine.

Moreover,  increased research activities will develop customized prospects for the industry to develop throughout the forecast period. Advancements in medical technology increase public and private sector attempt to raise awareness, and increased government financing will all contribute to the growth of the human immunodeficiency virus drugs industry. Other reasons, such as an increase in consumption of effective medicines and a rising acceptance rate for early genetic counseling, would have a positive impact on the growth rate of the industry. Furthermore, the rise of the industry will be fueled by increased disposable income, an increase in the number of occurrences of seizures, and a shift in lifestyle.

The hospital pharmacies segment accounted for the leading share in the industry. The category is expanding due to an increase in patient visits to hospitals for HIV drug treatment. In addition, rising sales of recommended antiretroviral medications for HIV therapy from hospital pharmacies would drive segmental growth.

Where is the Human Immunodeficiency Virus (HIV) Drugs Market Headed?

As per our recent study on the HIV drugs market, increasing research and development (R&D) in HIV drugs are expected to create lucrative opportunities for industry players in the coming years.  As per our observations, biopharma companies are investing in next-gen therapies, including long-acting, easier dosing, and new mechanisms. Since older therapies commoditize, next-gen therapies will differentiate and maintain growth. According to the geographic analysis, Asia Pacific is expected to witness the highest CAGR in the global market during the forecast period. The regional market growth is attributed to the high HIV-infected population, improved healthcare infrastructure, and an increase in the rate of HIV diagnosis and drug treatment.

What Does the Human Immunodeficiency Virus (HIV) Drugs Report Reveal?

• What is the global market size, future industry trends, and CAGR for the industry through 2030?
• What are the factors driving the industry growth?
• Who are the key industry players, and what is their relative position in terms of competitive positioning?
• How do different distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, influence the market landscape?
• How does the market differ in drug class, distribution channel, and geography?
• What are the trends in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?
• Where do new opportunities arise in the market?

Market players such as Roche Ltd., Boehringer Ingelheim, GlaxoSmithKline plc., Gilead Sciences, Inc., Johnson & Johnson, Merck, Pfizer Inc., Cipla Limited, and Teva Pharmaceutical Industries Ltd. are key players operating in the industry. In March 2021, Merck and Gilead signed a cooperation agreement to commercialize HIV therapy. This two-drug combination includes Gilead's “lenacapavir” and Merck's islatravir.

Request a free sample copy or read the full market insights: Human Immunodeficiency Virus (HIV) Drugs Market

Polaris Market Research has segmented the Human Immunodeficiency Virus (HIV) drugs market report based on drug class, distribution channel, and region:

Human Immunodeficiency Virus (HIV) Drugs, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)

• Nucleoside Reverse Transcriptase Inhibitors
• Multi-Class Combination Products
• Protease Inhibitors
• HIV Integrase Strand Transfer Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Entry Inhibitors - CCR5 Co-Receptor Antagonist
• Fusion Inhibitors
• Others

Human Immunodeficiency Virus (HIV) Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Human Immunodeficiency Virus (HIV) Drugs, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

• North America
  • U.S.
  • Canada
• Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
• Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
• Latin America
  • Mexico
  • Brazil
  • Argentina
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa